The Future of Antiangiogenic Drugs Hinges on Identification of Biomarkers
March 12th 2013So far, there are no conclusive biomarkers to help identify subsets of patients who would benefit from antiangiogenic therapies, creating a barrier to the use of such treatments, Rugo said in her MBCC abstract.
Read More
The Evolution of Gene Expression Profiling: Its Role in Informing Selection of Systemic Therapy
March 9th 2013Gene expression profiling via the Oncotype DX 21-gene recurrence score assay has been used to assess risk and predict recurrence in hundreds of thousands of women over the course of nearly a decade.
Read More
Exploring New Genomic Targets in Metastatic Disease
March 8th 2013Fabrice André, MD, PhD, has focused his research on translational oncology and the development of novel targeted agents for the treatment of breast cancer through his research as director of INSERM Unit U981 at the Institut Gustave-Roussy in Villejuif, France.
Read More
Quizartinib Sparks Remission in Some Patients With Resistant AML
December 18th 2012Quizartinib, a novel tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia in results of a phase II study presented during the 54th Annual ASH Meeting.
Read More
Novel JAK2 Inhibitor Shows Promise as Myelofibrosis Therapy
December 14th 2012An investigational, selective JAK2 inhibitor known as SAR302503 reduced spleen size in patients with myelofibrosis, according to phase II data presented at the 2012 American Society of Hematology Annual Meeting and Exposition.
Read More
Ibrutinib Performance in CLL Patients Hailed
December 13th 2012The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab, raising the prospect of a promising new therapy for elderly and frail patients who currently have few viable options.
Read More
Pomalidomide Labeled an Advance in Multiple Myeloma
December 9th 2012The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Read More
Ponatinib Stimulates ‘Powerful’ Response in Treatment-Resistant Leukemias
December 8th 2012Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance—including the stubborn T315I mutation—in all stages of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Read More